Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02009384
Other study ID # BCC-MEL-11-01
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date January 2012
Est. completion date October 2014

Study information

Verified date October 2021
Source University of Louisville
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, clinical efficacy study of Ipilimumab in patients with Stage IIIC and Stage IV melanoma who have recently been treated with Denileukin Diftitox. Approximately 42 patients with radiographically measurable melanoma who have received at least one cycle of Denileukin Diftitox will be enrolled and treated in the study.


Description:

This is an open-label, clinical efficacy study of Ipilimumab in patients with Stage IIIC and Stage IV melanoma who have recently been treated with Denileukin Diftitox. Approximately 42 patients with radiographically measurable melanoma who have received at least one cycle of Denileukin Diftitox will be enrolled and treated in the study.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female patients =18 years of age; 2. Patients with histological confirmed melanoma (Stage IIIC or Stage IV, American Joint Commission on Cancer); 3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2; 4. Life expectancy =3 months; 5. Treatment with Denileukin Diftitox within 42 days prior to first dose of Ipilimumab; 6. At least 1 site of radiographically measurable disease by immune-related response criteria (irRC); 7. Adequate hematologic, renal, and liver function as defined by laboratory values performed within 42 days prior to initiation of dosing: - Absolute neutrophil count (ANC) =1.0 x 109/L; - Platelet count =100 x 109/L; - Hemoglobin =8 g/dL; - Serum creatinine =3 x upper limit of normal (ULN) - Total serum bilirubin =2 x ULN; - Serum aspartate transaminase (AST/SGOT) or serum alanine transaminase (ALT/SGPT) =2x ULN, and =3 x ULN if liver metastases are present. 8. Fertile males should use an effective method of contraception during treatment and for at least 3 months after completion of treatment, as directed by their physician; 9. Pre-menopausal females and females <2 years after the onset of menopause should have a negative pregnancy test at Screening. Pre-menopausal females must agree to use an acceptable method of birth control from the time of the negative pregnancy test up to 90 days after the last dose of study drug. Females of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for =1 year; 10. Before study entry, written informed consent must be obtained from the patient prior to performing any study-related procedures. Exclusion Criteria: 1. Prior treatment with Ipilimumab; 2. Known hypersensitivity to Ipilimumab or any of its components; 3. Steroids within one week prior to initiation of Ipilimumab. 4. Pre-existing autoimmune colitis. 5. Patients with an allograft requiring immunosuppression; 6. Known positive human immunodeficiency virus (HIV) 7. Pregnant, breast-feeding, or refusing double barrier contraception, oral contraceptives, or avoidance of pregnancy measures; 8. Have any other uncontrolled infection or medical condition that could interfere with the conduct of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ipilimumab
administration of IV ipilimumab for up to 4 cycles

Locations

Country Name City State
United States James Graham Brown Cancer Center Louisville Kentucky

Sponsors (2)

Lead Sponsor Collaborator
University of Louisville James Graham Brown Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline Using Immune-related Response Criteria (irRC) no outcomes available, Study was Terminated due to low subject enrollment [r/t requirement of prior treatment with denileukin diftitox] Data was not analyzed baseline, 12 weeks, 24 weeks, 36 weeks, 48 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02224781 - Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma Phase 3
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05388877 - E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma Phase 1
Active, not recruiting NCT05103891 - Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations Phase 1
Completed NCT00414765 - Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma Phase 4
Completed NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Phase 1
Completed NCT01621490 - PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma Phase 1
Recruiting NCT05779423 - Cryoablation+Ipilimumab+Nivolumab in Melanoma Phase 2
Active, not recruiting NCT04940299 - Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Phase 2
Active, not recruiting NCT02278887 - Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma Phase 3
Active, not recruiting NCT02360579 - Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma Phase 2
Terminated NCT02521870 - A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase 1/Phase 2
Completed NCT02177110 - A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Withdrawn NCT01340729 - Open-Label Study of TPI 287 for Patients With Metastatic Melanoma Phase 1/Phase 2
Withdrawn NCT01416844 - Study of Immune Responses in Patients With Metastatic Melanoma Phase 2
Terminated NCT01468818 - Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma Phase 2
Completed NCT00984464 - Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma Phase 2
Completed NCT00631618 - Clinical Trial of Sutent to Treat Metastatic Melanoma Phase 2
Terminated NCT00571116 - Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy Phase 1
Recruiting NCT00226473 - Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Phase 4